Combining ICI with adoptive T-cell therapies to treat cancer has been shown to increase persistence and effector function, especially with anti-PD-1 (Burga et al., 2015; Gargett et al., 2016; Najafi and Mortezaee, 2023). This evidence concerns the gene PDCD1 and cancer.